NVO vs VKTX
NVO: A global leader in the development of pharmaceutical treatments for diabetes, obesity, and rare chronic diseases, anchored by its prominent GLP-1 therapy portfolio. VKTX: A clinical-stage biopharmaceutical company developing next-generation dual GLP-1/GIP receptor agonists for the treatment of obesity and metabolic disorders.
Side-by-side fundamentals
| Metric | NVO | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $38.18 | $27.73 | |
| Market cap | $206.0B | $3.2B | |
| P/E as of 2026-09-03 | 11.40 | n/a | |
| Net margin FY2025, SEC XBRL | +33.1% | n/a | |
| Gross margin FY2025, SEC XBRL | +81.0% | n/a | |
| Operating margin FY2025, SEC XBRL | +41.3% | n/a | |
| ROE FY2025, SEC XBRL | +52.8% | -56.3% | NVO higher |
| ROA FY2025, SEC XBRL | +18.9% | -50.2% | NVO higher |
| Debt / equity as of 2026-09-03 | 0.63 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +20.4% | n/a | |
| Dividend yield as of 2026-09-03 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.81 | 1.47 | |
| 1-year return as of 2026-10-08 close | -36.0% | -14.3% | VKTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.